One step back to move forward in oncology workforce
The scope of the oncology care across resource-diverse settings has been long debated.
Good night for good? Preventing sleeping cancer cells from awakening
Metastases are the main cause of cancer-related deaths. Preventing hibernating cancer cells from awakening therefore represents an urgent, unmet medical need.
Milestone in hereditary breast cancer: PARP inhibition benefits women with early-stage disease
Exciting new data show that adjuvant targeted agent olaparib after chemotherapy can cut the risk of BRCA-mutated breast cancer returning or spreading in women
Making assumptions about COVID-19 and cancer: a way to harm all
Conquering cancer: an attainable goal?
Following more than two decades of extraordinary developments and advancements in cancer research – from molecular mechanisms to clinical care to new enabling technologies, we are better equipped than ever before to deliver a much more personalised, targeted form of cancer treatment and care.
Hereditary cancers: diagnosed patients are only the tip of the iceberg
Although knowledge on pathogenic germline variants has improved over the years, researchers are hunting for new genetic causes of cancer to better identify families at higher risk to develop the disease
Despite success of targeted therapies, personalised medicine is not yet a reality in ovarian cancer
Expert says widely applicable predictive testing is needed to improve prevention, diagnosis and treatment
Patients need more support to navigate precision oncology
As the complexity of the cancer landscape increases, miscommunication and misunderstanding emerge as major obstacles to patient self-determination
Predict the next evolutionary move of cancer: a feasible winning strategy?
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end